SCHEMBL4901455

SCHEMBL4901455

COC(=O)c1ccc(-c2c[nH]c(=O)n2Cc2ccc(CP(=O)(OF)OF)c(Br)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 4/20 0.37
ALDH1A1 P00352 1/20 0.37
DRD2 P14416 1/20 0.36
TBXA2R P21731 1/20 0.36
HIF1A Q16665 1/20 0.35
MAPK8 P45983 1/20 0.35
CCR6 P51684 1/20 0.35
HKDC1 Q2TB90 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
MCHR1 Q99705 1/20 0.34
CHKA P35790 1/20 0.33
USP2 O75604 1/20 0.33
EP300 Q09472 1/20 0.33
CNR2 P34972 1/20 0.33
RXFP1 Q9HBX9 1/20 0.33
LMNA P02545 1/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4891795 0.90 ALDH1A1 (0.34) MAPK10ALDH1A1HIF1AMAPK8MEN1
SCHEMBL4891983 0.88 MAPK10 (0.37) MAPK10ALDH1A1DRD2TBXA2RHIF1A
SCHEMBL4891992 0.84 MAPK10 (0.39) MAPK10ALDH1A1HIF1AMAPK8CCR6
SCHEMBL4890554 0.83 MAPK10 (0.38) MAPK10ALDH1A1HIF1AMAPK8CCR6
SCHEMBL4899314 0.82 MAPK10 (0.37) MAPK10ALDH1A1HIF1AMAPK8CCR6
SCHEMBL4899408 0.82 HDAC1 (0.42) MAPK10ALDH1A1DRD2TBXA2RMAPK8
SCHEMBL4901331 0.81 MAPK10 (0.42) MAPK10ALDH1A1DRD2TBXA2RHIF1A
SCHEMBL4893914 0.81 MAPK10 (0.36) MAPK10ALDH1A1HIF1AMAPK8CCR6
SCHEMBL4903709 0.81 MAPK10 (0.42) MAPK10ALDH1A1DRD2TBXA2RHIF1A
SCHEMBL4900023 0.81 MAPK10 (0.40) MAPK10ALDH1A1HIF1AMAPK8USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US claimed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO claimed
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases METABASIS THERAPEUTICS, INC. (US) 2008-03-20 US disclosed
WO-2006078698-A1 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES CENGENT THERAPEUTICS, INC. (US) 2006-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070867-A1 2-Imidazolone and 2-Imidazolidinone Heterocyclic Inhibitors of Tyrosine Phosphatases PPM1B, PPM1D, PTPRS MAPK10 656/4885ALDH1A1 3704/4885DRD2 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.